ARQT earnings: real EPS beat/miss history, analyst consensus Buy, P/E -1453.13. Updated 2026-07-23.
Arcutis Biotherapeutics (ARQT) Research Hub
Arcutis Biotherapeutics (ARQT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 23.885 USD (+0.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1453.13, market cap 3.48B. This hub links to the full technical, earnings and options research available for ARQT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.885 USD (+0.19%) |
| 52-week range | 23.27 USD – 29.84 USD |
| Trend regime | Range |
| 14-day RSI | 40.1 (Bearish) |
| Trailing P/E | -1453.13 |
| Market cap | 3.48B |
| Dividend yield | 0.00% |
Available research for ARQT
Covered Call on ARQT: how it works, illustrative setup around the real 23.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ARQT: how it works, illustrative setup around the real 23.89 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ARQT: how it works, illustrative setup around the real 23.89 USD price, max profit/loss, breakeven and when to use it. Educational.
ARQT technical analysis: range, last 23.885 USD, RSI 40.1, 52w range 23.27 USD–29.84 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ARQT in?
Arcutis Biotherapeutics (ARQT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ARQT in an uptrend or downtrend?
As of 2026-09-11, ARQT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ARQT's trailing P/E ratio?
ARQT's trailing P/E is -1453.13, with a market cap of 3.48B. See the earnings research page for full valuation detail.